Orgenesis (NASDAQ:ORGS – Get Rating) issued its quarterly earnings results on Monday. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by ($0.12), Fidelity Earnings reports. Orgenesis had a return on equity of 16.12% and a net margin of 22.02%.
Shares of NASDAQ ORGS traded up $0.05 during mid-day trading on Tuesday, hitting $2.15. The company had a trading volume of 900 shares, compared to its average volume of 47,406. The company has a market capitalization of $53.37 million, a PE ratio of 6.56 and a beta of 0.90. The business’s 50-day simple moving average is $3.15 and its 200 day simple moving average is $3.13. Orgenesis has a 1-year low of $2.03 and a 1-year high of $5.85. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.68 and a quick ratio of 1.67.
A number of hedge funds have recently bought and sold shares of the business. Morgan Stanley increased its position in shares of Orgenesis by 2,033.1% in the 2nd quarter. Morgan Stanley now owns 8,127 shares of the company’s stock valued at $41,000 after purchasing an additional 7,746 shares during the last quarter. Royal Bank of Canada grew its stake in shares of Orgenesis by 225.5% during the second quarter. Royal Bank of Canada now owns 5,677 shares of the company’s stock worth $29,000 after purchasing an additional 3,933 shares in the last quarter. Dimensional Fund Advisors LP increased its holdings in Orgenesis by 31.9% in the third quarter. Dimensional Fund Advisors LP now owns 25,254 shares of the company’s stock valued at $125,000 after buying an additional 6,109 shares during the last quarter. Susquehanna International Group LLP raised its stake in Orgenesis by 166.0% in the fourth quarter. Susquehanna International Group LLP now owns 12,400 shares of the company’s stock valued at $36,000 after buying an additional 31,200 shares in the last quarter. Finally, Virtu Financial LLC acquired a new stake in Orgenesis in the fourth quarter valued at $95,000. 15.15% of the stock is currently owned by institutional investors.
Orgenesis Inc, a biotech company, focusing on cell and gene therapies worldwide. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed POCare therapeutics that are processed and produced in closed automated POCare technology systems across a collaborative POCare network.
- Get a free copy of the StockNews.com research report on Orgenesis (ORGS)
- Zoom Video Communications Is Primed To Launch Higher
- Fundamental Strength Makes Williams-Sonoma One for Your Recovery Watchlist
- Institutions Buy The Dip In Petco Health and Wellness Company
- Veeva Systems: Increasing NDR and Other Wins
- Autozone Edges Past Advanced Auto Parts In Q1 2022
Receive News & Ratings for Orgenesis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orgenesis and related companies with MarketBeat.com's FREE daily email newsletter.